Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorV. Beralen_US
dc.contributor.authorR. Dollen_US
dc.contributor.authorC. Hermonen_US
dc.contributor.authorR. Petoen_US
dc.contributor.authorG. Reevesen_US
dc.contributor.authorL. Brintonen_US
dc.contributor.authorA. C. Greenen_US
dc.contributor.authorP. Marchbanksen_US
dc.contributor.authorE. Negrien_US
dc.contributor.authorR. Nessen_US
dc.contributor.authorP. Peetersen_US
dc.contributor.authorM. Vesseyen_US
dc.contributor.authorE. E. Calleen_US
dc.contributor.authorC. Rodriguezen_US
dc.contributor.authorL. Dal Masoen_US
dc.contributor.authorR. Talaminien_US
dc.contributor.authorD. Crameren_US
dc.contributor.authorS. E. Hankinsonen_US
dc.contributor.authorS. S. Tworogeren_US
dc.contributor.authorA. Chetriten_US
dc.contributor.authorG. Hirsh-Yechezkelen_US
dc.contributor.authorF. Lubinen_US
dc.contributor.authorS. Sadetzkien_US
dc.contributor.authorP. Applebyen_US
dc.contributor.authorE. Banksen_US
dc.contributor.authorA. Berrington de Gonzalezen_US
dc.contributor.authorD. Bullen_US
dc.contributor.authorB. Crossleyen_US
dc.contributor.authorA. Goodillen_US
dc.contributor.authorI. Greenen_US
dc.contributor.authorJ. Greenen_US
dc.contributor.authorT. Keyen_US
dc.contributor.authorR. Collinsen_US
dc.contributor.authorC. A. Gonzalezen_US
dc.contributor.authorN. Leeen_US
dc.contributor.authorH. W. Oryen_US
dc.contributor.authorH. B. Petersonen_US
dc.contributor.authorP. A. Wingoen_US
dc.contributor.authorN. Martinen_US
dc.contributor.authorT. Pardthaisongen_US
dc.contributor.authorS. Silpisornkosolen_US
dc.contributor.authorC. Theetranonten_US
dc.contributor.authorB. Boosirien_US
dc.contributor.authorS. Chutivongseen_US
dc.contributor.authorP. Jimakornen_US
dc.contributor.authorP. Virutamasenen_US
dc.contributor.authorC. Wongsrichanalaien_US
dc.contributor.authorL. Titus-Ernstoffen_US
dc.contributor.authorB. J. Mosgaarden_US
dc.contributor.authorD. Yeatesen_US
dc.contributor.authorJ. Chang-Claudeen_US
dc.contributor.authorM. A. Rossingen_US
dc.contributor.authorD. Thomasen_US
dc.contributor.authorN. Weissen_US
dc.contributor.authorS. Franceschien_US
dc.contributor.authorC. La Vecchiaen_US
dc.contributor.authorH. O. Adamien_US
dc.contributor.authorC. Magnussonen_US
dc.contributor.authorT. Rimanen_US
dc.contributor.authorE. Weiderpassen_US
dc.contributor.authorA. Wolken_US
dc.contributor.authorL. A. Brintonen_US
dc.contributor.authorD. M. Freedmanen_US
dc.contributor.authorP. Hartgeen_US
dc.contributor.authorJ. M. Laceyen_US
dc.contributor.authorR. Hooveren_US
dc.contributor.authorL. J. Schoutenen_US
dc.contributor.authorP. A. van den Brandten_US
dc.contributor.authorN. Chantarakulen_US
dc.contributor.authorS. Koetsawangen_US
dc.contributor.authorD. Rachawaten_US
dc.contributor.authorS. Graff-Iversenen_US
dc.contributor.authorR. Selmeren_US
dc.contributor.authorC. J. Bainen_US
dc.contributor.authorD. M. Purdieen_US
dc.contributor.authorV. Siskinden_US
dc.contributor.authorP. M. Webben_US
dc.contributor.authorS. E. McCannen_US
dc.contributor.authorP. Hannaforden_US
dc.contributor.authorC. Kayen_US
dc.contributor.authorC. W. Binnsen_US
dc.contributor.authorA. H. Leeen_US
dc.contributor.authorM. Zhangen_US
dc.contributor.authorP. Nascaen_US
dc.contributor.authorP. F. Cooganen_US
dc.contributor.authorL. Rosenbergen_US
dc.contributor.authorJ. Kelseyen_US
dc.contributor.authorR. Paffenbargeren_US
dc.contributor.authorA. Whittemoreen_US
dc.contributor.authorK. Katsouyannien_US
dc.contributor.authorA. Trichopoulouen_US
dc.contributor.authorD. Trichopoulosen_US
dc.contributor.authorA. Tzonouen_US
dc.contributor.authorA. Dabancensen_US
dc.contributor.authorL. Martinezen_US
dc.contributor.authorR. Molinaen_US
dc.contributor.authorO. Salasen_US
dc.contributor.authorM. T. Goodmanen_US
dc.contributor.authorG. Laurieen_US
dc.description.abstractBackground: Oral contraceptives were introduced almost 50 years ago, and over 100 million women currently use them. Oral contraceptives can reduce the risk of ovarian cancer, but the eventual public-health effects of this reduction will depend on how long the protection lasts after use ceases. We aimed to assess these effects. Methods: Individual data for 23 257 women with ovarian cancer (cases) and 87 303 without ovarian cancer (controls) from 45 epidemiological studies in 21 countries were checked and analysed centrally. The relative risk of ovarian cancer in relation to oral contraceptive use was estimated, stratifying by study, age, parity, and hysterectomy. Findings: Overall 7308 (31%) cases and 32 717 (37%) controls had ever used oral contraceptives, for average durations among users of 4·4 and 5·0 years, respectively. The median year of cancer diagnosis was 1993, when cases were aged an average of 56 years. The longer that women had used oral contraceptives, the greater the reduction in ovarian cancer risk (p<0·0001). This reduction in risk persisted for more than 30 years after oral contraceptive use had ceased but became somewhat attenuated over time-the proportional risk reductions per 5 years of use were 29% (95% CI 23-34%) for use that had ceased less than 10 years previously, 19% (14-24%) for use that had ceased 10-19 years previously, and 15% (9-21%) for use that had ceased 20-29 years previously. Use during the 1960s, 1970s, and 1980s was associated with similar proportional risk reductions, although typical oestrogen doses in the 1960s were more than double those in the 1980s. The incidence of mucinous tumours (12% of the total) seemed little affected by oral contraceptives, but otherwise the proportional risk reduction did not vary much between different histological types. In high-income countries, 10 years use of oral contraceptives was estimated to reduce ovarian cancer incidence before age 75 from 1·2 to 0·8 per 100 users and mortality from 0·7 to 0·5 per 100; for every 5000 woman-years of use, about two ovarian cancers and one death from the disease before age 75 are prevented. Interpretation: Use of oral contraceptives confers long-term protection against ovarian cancer. These findings suggest that oral contraceptives have already prevented some 200 000 ovarian cancers and 100 000 deaths from the disease, and that over the next few decades the number of cancers prevented will rise to at least 30 000 per year. © 2008 Elsevier Ltd. All rights reserved.en_US
dc.titleOvarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23 257 women with ovarian cancer and 87 303 controlsen_US
article.title.sourcetitleThe Lanceten_US
article.volume371en_US Cancer Societyen_US Centro Di Riferimento Oncologico Avianoen_US and Women's Hospitalen_US Laboratoryen_US Gertner Instituteen_US Epidemiology Uniten_US Trial Service Uniten_US Catala Oncologiaen_US for Disease Control and Preventionen_US Mai Universityen_US Universityen_US School of Medicine at Dartmouthen_US i Herleven_US of Public Healthen_US Cancer Research Centeren_US of Washington, Seattleen_US Agency for Research on Canceren_US degli Studi di Milanoen_US Instituteten_US Cancer Instituteen_US Universityen_US Universityen_US Institute of Public Healthen_US of Queenslanden_US Park Cancer Instituteen_US College of General Practitioners Oral Contraception Studyen_US Universityen_US of Massachusetts Systemen_US Universityen_US Universityen_US of Athens Medical Schoolen_US de Chileen_US of Hawaii Systemen_US Medical Center Utrechten_US
Appears in Collections:CMUL: Journal Articles

Files in This Item:
There are no files associated with this item.

Items in CMUIR are protected by copyright, with all rights reserved, unless otherwise indicated.